IGHV3OR16-13

Across TCGA pan-cancer cohorts, IGHV3OR16-13 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated IGHV3OR16-13 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher IGHV3OR16-13 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated IGHV3OR16-13 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

CCRCC and LUAD are the cancer types where IGHV3OR16-13 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	II,III,IV	0.270	0.785	.022	2	view →
LUAD	DFS	Quartile	II,III,IV	1.000	0.290	.049	2	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

IGHV3OR16-13–CCRCC (DFS)

Open the CCRCC breakdown →